St armands...I still am holding all my shares and have decided to wait out the "EMEA" ruling. I like others was surprised by the recent financing, but after discussing the situation with my spouse, we are going wait. I sincerely hope the recent financing does not reflect GTCB senior management’s opinion of ATryn chances of approval in October. After going through two sets of Q&A with the EMEA, I believe they (EMEA) will either give a positive ruling or flag the project. FWIW IMHO.
I wouldn't worry - it's just August, and nothing is happening in biotech, except shorting of course.
As to the financing, well it's been debated here, but if you were manamgement, you would probably want the cash as insurance, just-in-case; better get $1.85 than $0.85 per share if the EMEA stalled us again.
News 
Market Data 
Discover 
AI
